United Therapeutics investor relations material

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company markets vasopressin receptor antagonists; Atrasentan, an endothelin receptor antagonist; Leflunomide, an immunomodulator; Pazopanib, a vascular endothelial growth factor inhibitor for the treatment of advanced renal cell carcinoma; Aranesp and Nplate for anemia; and Votrient for hepatocellular carcinoma. It also develops Auristatin peptide analog therapeutics as anticancer agents. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.